RESULTS	Patients treated with Montelukast improved their nasal symptoms ( Delta HRQL-score 0.58 + / - 0.94 , P < 0.01 ) , practical problems ( Delta HRQL-score 0.42 + / - 0.71 , P < 0.05 ) , headaches ( Delta HRQL-score 0.38 + / - 0.56 , P < 0.05 ) , non-nasal symptoms ( Delta HRQL-score 0.35 + / - 0.92 , P < 0.05 ) , sleep ( Delta HRQL-score 0.26 + / - 0.71 ) and emotional problems ( Delta HRQL-score 0.18 + / - 0.75 ) .\